Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial - Sorbonne Université
Journal Articles European Journal of Cancer Year : 2021

Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial

Alice Boilève
  • Function : Author
Institut Gustave Roussy
Cooperator Multidisciplinary Oncology Group
Marc Hilmi
  • Function : Author
Cooperator Multidisciplinary Oncology Group
Institut Curie [Paris]
Paul Gougis
  • Function : Author
Centre d'investigation clinique Paris Est [CHU Pitié Salpêtrière]
CHU Pitié-Salpêtrière [AP-HP]
Romain Cohen
  • Function : Author
Cooperator Multidisciplinary Oncology Group
CHU Saint-Antoine [AP-HP]
Benoît Rousseau
  • Function : Author
Jean-Frédéric Blanc
  • Function : Author
Centre Hospitalier Universitaire de Bordeaux
Meher Ben Abdelghani
  • Function : Author
Institut de Cancérologie de Strasbourg Europe
Hélène Castanié
  • Function : Author
Laëtitia Dahan
  • Function : Author
Hôpital de la Timone [CHU - APHM]
David Tougeron
  • Function : Author
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
Jean-Philippe Metges
  • Function : Author
Centre Hospitalier Régional Universitaire de Brest
Christophe Tournigand
  • Function : Author
Cooperator Multidisciplinary Oncology Group
Marie-Line Garcia-Larnicol
  • Function : Author
Cooperator Multidisciplinary Oncology Group
Dewi Vernerey
  • Function : Author
Cooperator Multidisciplinary Oncology Group
Service d'Oncologie Médicale [CHRU Besançon]
Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)
Anthony Turpin
Cooperator Multidisciplinary Oncology Group
Service d'oncologie médicale (CHRU Lille)
Cindy Neuzillet
Institut Curie [Paris]
UFR Sciences de la santé Simone Veil

Domains

Cancer
Fichier principal
Vignette du fichier
S0959804920313137.pdf (550.81 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Accord Elsevier CCSD  : Connect in order to contact the contributor

https://hal.science/hal-04548022

Submitted on : Friday, November 29, 2024-4:40:54 PM

Last modification on : Saturday, November 30, 2024-3:28:22 AM

Download

Dates and versions

hal-04548022 , version 1 (29-11-2024)

Licence

Attribution - NonCommercial

Identifiers

Elsevier-hosted Accepted Manuscript

Cite

Alice Boilève, Marc Hilmi, Paul Gougis, Romain Cohen, Benoît Rousseau, et al.. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. European Journal of Cancer, 2021, 143, pp.55-63. ⟨10.1016/j.ejca.2020.10.027⟩. ⟨hal-04548022⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

UNIV-FCOMTE FNCLCC CURIE UVSQ PSL UNIV-PARIS-SACLAY SORBONNE-UNIVERSITE SU-MEDECINE
13 View
0 Download

Altmetric

Share

More